APTO Projected Dividend Yield
Aptose Biosciences Inc ( NASDAQ : APTO )Aptose Biosciences is biotechnology company developing agents to treat medical needs in cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Co.'s product pipeline includes cancer drug candidates that exert potent activity as stand-alone agents and that improve the activities of other anticancer agents without causing overlapping toxicities. Co.'s clinical-stage programs include: CG-806, which is a mutation-agnostic FMS-like tyrosine kinase 3 / Bruton's tyrosine kinase inhibitor; and APTO-253, which is a small molecule MYC oncogene inhibitor. 20 YEAR PERFORMANCE RESULTS |
APTO Dividend History Detail APTO Dividend News APTO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |